GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,476.00GBp
9:43am EDT
Price Change (% chg)

13.00p (+0.89%)
Prev Close
1,463.00p
Open
1,463.00p
Day's High
1,478.50p
Day's Low
1,463.00p
Volume
3,298,331
Avg. Vol
8,058,085
52-wk High
1,709.00p
52-wk Low
1,365.00p

GSK.L

Chart for GSK.L

About

GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in... (more)

Overall

Beta: 0.48
Market Cap (Mil.): £70,948.64
Shares Outstanding (Mil.): 4,849.53
Dividend: 19.00
Yield (%): 5.47

Financials

  GSK.L Industry Sector
P/E (TTM): 15.05 32.64 33.56
EPS (TTM): 0.97 -- --
ROI: 18.08 18.00 17.31
ROE: 75.85 18.64 18.05
Search Stocks

Ebola vaccine from GSK fast-tracked into clinical trials

LONDON/NEW YORK - An experimental Ebola vaccine from GlaxoSmithKline is being fast-tracked into human studies and the company plans to build a stockpile of up to 10,000 doses for emergency deployment, if results are good.

28 Aug 2014

UPDATE 1-Ebola vaccine from GSK fast-tracked into clinical trials

* Trials to vaccinate healthy volunteers from mid-September

28 Aug 2014

Ebola vaccine from GSK to begin U.S. clinical trials within weeks: sources

NEW YORK - U.S. health officials will announce on Thursday that a human study of an Ebola vaccine made by GlaxoSmithKline will begin within a couple of weeks and not later this year as the company estimated originally, according to people familiar with the plans.

27 Aug 2014

Ebola vaccine from GSK to begin U.S. clinical trials within weeks-sources

NEW YORK, Aug 27 - U.S. health officials will announce on Thursday that a human study of an Ebola vaccine made by GlaxoSmithKline will begin within a couple of weeks and not later this year as the company estimated originally, according to people familiar with the plans.

27 Aug 2014

INDIA PRESS-GlaxoSmithKline looks to invest 10 bln rupees in new health drink unit - Economic Times

Note: Reuters has not verified this story and does not vouch for its accuracy. (Compiled by Derek Francis in Bangalore)

21 Aug 2014

GSK-linked investigators will not appeal China sentence: lawyer

SHANGHAI - British corporate investigator Peter Humphrey and his American wife Yu Yingzeng do not plan to appeal a Chinese court's decision to sentence them to prison, a lawyer told Reuters on Friday.

15 Aug 2014

GSK-linked investigators will not appeal China sentence-lawyer

SHANGHAI, Aug 15 - British corporate investigator Peter Humphrey and his American wife Yu Yingzeng do not plan to appeal a Chinese court's decision to sentence them to prison, a lawyer told Reuters on Friday.

15 Aug 2014

Exclusive: GlaxoSmithKline faces fresh drug bribery claims in Syria

LONDON - GlaxoSmithKline faces new allegations that it bribed Syrian doctors and officials to boost sales of its medicines, following recent accusations of corruption in its non-prescription business in the country.

11 Aug 2014

Clinical trial to start soon on GSK Ebola vaccine

* Drugmaker working on experimental vaccine with U.S. NIAID

10 Aug 2014

RPT-U.S. emergency labs ready to work on Ebola drugs if asked

(Repeating story first sent on Aug 9 to additional subscribers)

10 Aug 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks